ProCE Banner Activity

JAK2 V617F Molecular Response to Long-term Ruxolitinib Therapy in Patients With PV and ET

Slideset Download
Conference Coverage

In patients with PV and ET treated with long-term ruxolitinib, JAK2 V617F complete molecular response or deep molecular response occurred in 18% of patients and was associated with lower risk of progression to secondary MF

Released: December 19, 2022

Expiration: December 18, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen